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Purpose
Osteopontin (OPN) is a secreted phosphoprotein func-
tioning in monocyte and T cell adhesion and migration.
Expression of OPN in alternatively-activated macrophages
has been implicated in post-inflammatory fibrosis of lung
and kidney. In our previously conducted cross-sectional
study of 72 pediatric SLE patients (pSLE; age of onset <18
years), increased circulating plasma OPN (cOPN) was
observed in pSLE compared with healthy controls, and
was associated of with ACR/SLICC damage index (SDI)
scores >1 (p = 0.0007 and 0.001, respectively), although
there was no association with SLEDAI. We therefore pro-
pose that OPN is a marker for pSLE disease progression,
and that increased cOPN levels may predict the develop-
ment of organ damage.
Methods
17 pSLE patients have been followed for at least 6 months
with cOPN measured by ELISA at baseline and at 6
month intervals. Serum Cr, urine protein/creatinine and
GFR were recorded at baseline and every 6 months. SLE-
DAI was recorded at 3 month intervals, and at disease
flare, and SDI at every 6 months. Cumulative disease activ-
ity (adjusted-mean SLEDAI, or AMS) was calculated by
finding the area under the curve of serial SLEDAI mea-
surements. Statistical analysis was performed using Stu-
dent’s t test, Pearson’s correlation, and Fisher’s exact test.
Results
6 of the 17 longitudinal subjects accumulated damage as
per an increase in SDI during the course of the study (3 in
the renal portion, 1 peripheral vascular, 1 pulmonary
hypertension, 1 avascular necrosis). 5 of the 6 patients
who accumulated damage had high cOPN levels (cOPN in
the top quartile) in at least 1 of the previous 2 visits prior
to the increase on SDI. 80% of subjects with a high cOPN
had an increase in SDI, whereas only 11% of subjects with
a cOPN in the bottom three quartiles had an increase in
SDI, indicating an increase in SDI was more likely in those
patients with a preceding high cOPN (p = 0.01). Cumula-
tive disease activity (AMS) was associated with an increase
in SDI scores (p < 0.0001) in this cohort, and was corre-
lated with cOPN levels (Spearman r = 0.46, p = 0.02).
Conclusion
cOPN is correlated with cumulative disease activity and
may be a potential marker for future organ damage in
pSLE. The rapid and/or early accrual of organ damage
in patients with SLE has been associated with poorer
outcomes, therefore a marker of risk for irreversible
damage could be a critical component for guiding treat-
ment decisions in pSLE.
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